
News|Articles|February 13, 2019
Talzenna for gBRCAm HER2-negative Locally Advanced or Metastatic Breast Cancer
Author(s)Drew Boxler
Advertisement
Talzenna (talazoparib, Pfizer)
Indications: Adult Patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.
Dosage: 1 mg singly oral daily dose until disease progression or unacceptable toxicity occurs
Contraindications: None
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
How Pharmacists Take Control of Medical Billing
2
Data Show Rise in GLP-1 Poison Center Calls Tied to Dosing Errors
3
Lowered Pneumococcal Vaccination Age Has Yet to Close Awareness Gap
4
FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol
5






























